Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1354897 | 0.81 | OPRD1 (0.41) | OPRD1PKMTSHRKDM4EGAA | |
| SCHEMBL6478611 | 0.78 | ELANE (0.39) | PKMTSHRKMT2A | |
| SCHEMBL6491384 | 0.77 | OPRD1 (0.51) | OPRD1TSHRKCNH2OPRK1 | |
| SCHEMBL6492765 | 0.76 | OPRD1 (0.39) | OPRD1PKMTSHRKCNH2OPRK1 | |
| SCHEMBL2004582 | 0.73 | TSHR (0.42) | PKMTSHRKDM4EGLAGAA | |
| SCHEMBL6480972 | 0.73 | OPRD1 (0.55) | OPRD1TSHRKDM4EGLAGAA | |
| SCHEMBL8657572 | 0.68 | PKM (0.42) | PKMTSHRCYP19A1KMT2A | |
| SCHEMBL7039789 | 0.66 | PKM (0.42) | PKMTSHRKDM4EGAACYP19A1 | |
| SCHEMBL276292 | 0.66 | PKM (0.47) | PKMTSHRCYP19A1KMT2A | |
| SCHEMBL7430943 | 0.66 | PKM (0.39) | PKMTSHRCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |